Monday 9 November 2020


Though preliminary reports are from a company press release and have not been independently verified, news that the COVID-19 candidate vaccine being developed and trialled by a partnership between the Mainz-based BioNTech and the US drug concern Pfizer vaccine exceeds effectiveness targets by a sizable margin (on par with the best childhood inoculations against measles) and suggests that protection is enduring is significant and hopeful. No serious safety concerns or side-effects were observed and the companies are already under contract to deliver tens of millions of doses.